{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T06:14:32Z","timestamp":1697350472274},"reference-count":27,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2009,3,9]],"date-time":"2009-03-09T00:00:00Z","timestamp":1236556800000},"content-version":"vor","delay-in-days":36,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ther Apher Dial"],"published-print":{"date-parts":[[2009,2]]},"abstract":"<jats:p><jats:bold>Abstract:\u2002<\/jats:bold> Hyperphosphatemia in dialysis patients is known to cause secondary hyperparathyroidism and high\u2010turnover bone disease. Sevelamer hydrochloride (sevelamer) is a nonabsorbed, calcium\u2010free phosphate\u2010binder. We determined the effect of sevelamer on parathyroid hormone (PTH)\u2010induced high bone turnover. Rats were sham\u2010operated or 5\/6\u2010nephrectomized (Nx) and fed a phosphate loading diet for 16\u2003weeks or 5\/6\u2010nephrectomized and fed a phosphate loading diet for 8\u2003weeks and then fed the same diet containing 3% sevelamer for the subsequent 8\u2003weeks (Nx\u2010S). Sevelamer significantly reduced serum PTH. The relative osteoid volume (OV\/BV), osteoid surface (OS\/BS), eroded surface (ES\/BS), mineral appositional rate (MAR), volume\u2010referent bone formation rate (BFR\/TV), and bone\u2010referent bone formation rate (BFR\/BV) were measured for vertebral bone histomorphometric analysis. All parameters were statistically higher in the Nx rats than in the sham\u2010operated control rats. The administration of sevelamer attenuated increases in OV\/BV, ES\/BS, BFR\/TV, and BFR\/BV. For femur histomorphometric analysis, the porosity area (%) (PoAr\/CtAr), osteoid surface on the periosteal surface, osteoid surface on the endocortical surface (OS\/Es), mineral appositional rate on the periosteal surface, mineral appositional rate on the endocortical surface, bone formation rate on the periosteal surface, and bone formation rate on the endocortical surface (Es BFR) were calculated. All parameters were higher in the Nx group than in the control group. Sevelamer inhibited the elevation of PoAr\/CtAr, OS\/Es, and Es BFR. Our findings suggest that the decrease in PTH by sevelamer may be beneficial in the treatment of high PTH\u2010induced bone disease.<\/jats:p>","DOI":"10.1111\/j.1744-9987.2009.00606.x","type":"journal-article","created":{"date-parts":[[2009,3,10]],"date-time":"2009-03-10T01:18:37Z","timestamp":1236647917000},"page":"42-48","source":"Crossref","is-referenced-by-count":2,"title":["Effect of Sevelamer Hydrochloride on Bone in Experimental Uremic Rats"],"prefix":"10.1111","volume":"13","author":[{"given":"Michio","family":"Kuwahara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seiji","family":"Inoshita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshio","family":"Terada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sei","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,3,9]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197205182862009"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI111365"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.1990.259.3.F432"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1994.408"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1053\/ajkd.1998.v31.pm9531176"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200005183422003"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2002.00434.x"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1744-9987.2006.00440.x"},{"issue":"3","key":"e_1_2_6_10_2","first-page":"S1","article-title":"K\/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease","volume":"42","author":"National Kidney Foundation","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(97)90009-3"},{"key":"e_1_2_6_12_2","first-page":"381","article-title":"Simultaneous lowering of serum phosphate and LDL\u2010cholesterol by sevelamer hydrochloride (RenaGel) in dialysis patients","volume":"50","author":"Wilkes BM","year":"1998","journal-title":"Clin Nephrol"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/13.9.2303"},{"key":"e_1_2_6_14_2","first-page":"18","article-title":"A randomized trial of sevelamer hydrochloride (RenaGel) with and without supplemental calcium. Strategies for the control of hyperphosphatemia and hyperparathyroidism in hemodialysis patients","volume":"51","author":"Chertow GM","year":"1999","journal-title":"Clin Nephrol"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(99)70221-0"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1053\/jren.2000.7410"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2004100885"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2003.00126.x"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ASN.0000025782.24383.0D"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/16.9.1870"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfg1021"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/s007740050096"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S8756-3282(02)00947-X"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.5650020617"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S8756-3282(98)00098-2"},{"key":"e_1_2_6_26_2","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1016\/S0021-9258(18)69191-4","article-title":"5\u2032\u2010flanking region of the parathyroid hormone gene mediates negative regulation by 1,25\u2010(OH)2 vitamin D3","volume":"263","author":"Okazaki T","year":"1988","journal-title":"J Biol Chem"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.89.17.8097"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI113946"}],"container-title":["Therapeutic Apheresis and Dialysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1744-9987.2009.00606.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1744-9987.2009.00606.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T11:24:08Z","timestamp":1697282648000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1744-9987.2009.00606.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,2]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,2]]}},"alternative-id":["10.1111\/j.1744-9987.2009.00606.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1744-9987.2009.00606.x","archive":["Portico"],"relation":{},"ISSN":["1744-9979","1744-9987"],"issn-type":[{"value":"1744-9979","type":"print"},{"value":"1744-9987","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,2]]}}}